中国中药(00570.HK)在2024年10月18日宣布,由于其境外直接投资未获批准,私有化建议告吹。受此消息影响,中国中药10月12日股价盘中一度大跌44%至2.12港元,股价2013年3月以来新低,成交超过5亿港元。市场人士认为,这次私有化计划的失败可能会对中国中药的股价和市场信心造成一定的影响。投资者对于公司的未来预期可能会有所调整,同时,公司可能需要重新考虑其战略方向和资本市场的定位。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.